UMEM Educational Pearls

Category: Infectious Disease

Title: New C. Diff Colitis Medication

Keywords: C. Diff Colitis (PubMed Search)

Posted: 7/16/2011 by Michael Bond, MD (Updated: 12/9/2019)
Click here to contact Michael Bond, MD

C. Diff Colitis

The general treatment recommendations for C. Diff Colitis are to place the patient on PO metronidazole and if they fail this treatment PO vancomycin (125 mg 4x day).  Vancomycin is generally reserved for resistant cases due to the fear that it could induce Vancomycin resistant enterococcus.

For severally ill patients it is recommended that you prescribe IV metronidazole and PO vancomycin when they are not actively vomiting.  Remember there is no role for IV vancomycin as it does not get into the bowel lumen to eradicate the infection.

There is some great news though, the FDA recently approved a new drug, a macrolide antibiotic fidaxomicin (Dificid), for the treatment of C. Diff Colitis. Fidaxomicin was found to be as effective as vancomycin in preventing recurrence 3 weeks after treatment.  Currently it is recommended that fidaxomicin be reserved for cases where patients are having recurrences after 3 weeks of vancomycin treatment.

The FDA news release can be found at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm